LIFECORE BIOMEDICAL, INC. Cost of Revenue
LIFECORE BIOMEDICAL, INC. (LFCR) reported Cost of Revenue of $106.22 million for the 3-month period ending 2014-02-23, per its 10-Q filed 2014-03-28.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2014-03-28
- LIFECORE BIOMEDICAL, INC. cost of revenue for the quarter ending 2014-02-23 was $106.22M, a 5.84% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of revenue for the quarter ending 2013-11-24 was $106.29M, a 10.50% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of revenue for the quarter ending 2013-08-25 was $96.95M, a 9.78% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of revenue for the quarter ending 2013-05-26 was $94.08M, a 38.54% increase year-over-year.
- LIFECORE BIOMEDICAL, INC. cost of revenue for fiscal 2013 was $378.95M, a 42.78% increase from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. cost of revenue for fiscal 2012 was $265.41M, a 15.38% increase from fiscal 2011.
- LIFECORE BIOMEDICAL, INC. cost of revenue for fiscal 2011 was $230.03M, a 12.51% increase from fiscal 2010.
- LIFECORE BIOMEDICAL, INC. cost of revenue for fiscal 2010 was $204.46M.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2014-02-23 | $106.22M 10-Q · filed 2014-03-28 | $212.52M derived: sum of 2 quarters · filed 2014-03-28 | $309.46M 10-Q · filed 2014-03-28 | $403.55M derived: sum of 4 quarters · filed 2014-03-28 |
| 2013-11-24 | $106.29M 10-Q · filed 2014-01-03 | $203.24M 10-Q · filed 2014-01-03 | $297.32M derived: sum of 3 quarters · filed 2014-01-03 | $397.68M derived: sum of 4 quarters · filed 2014-03-28 |
| 2013-08-25 | $96.95M 10-Q · filed 2013-09-26 | $191.03M derived: sum of 2 quarters · filed 2013-09-26 | $291.39M derived: sum of 3 quarters · filed 2014-03-28 | $387.58M derived: sum of 4 quarters · filed 2014-03-28 |
| 2013-05-26 | $94.08M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $194.44M derived: sum of 2 quarters · filed 2014-03-28 | $290.64M derived: sum of 3 quarters · filed 2014-03-28 | $378.95M 10-K · filed 2013-08-07 |
| 2013-02-24 | $100.36M 10-Q · filed 2014-03-28 | $196.55M derived: sum of 2 quarters · filed 2014-03-28 | $284.87M 10-Q · filed 2014-03-28 | $352.78M derived: sum of 4 quarters · filed 2014-03-28 |
| 2012-11-25 | $96.19M 10-Q · filed 2014-01-03 | $184.51M 10-Q · filed 2014-01-03 | $252.42M derived: sum of 3 quarters · filed 2014-01-03 | $319.31M derived: sum of 4 quarters · filed 2014-01-03 |
| 2012-08-26 | $88.31M 10-Q · filed 2013-09-26 | $156.22M derived: sum of 2 quarters · filed 2013-09-26 | $223.11M derived: sum of 3 quarters · filed 2013-09-26 | $291.67M derived: sum of 4 quarters · filed 2013-09-26 |
| 2012-05-27 | $67.91M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $134.80M derived: sum of 2 quarters · filed 2013-08-07 | $203.36M derived: sum of 3 quarters · filed 2013-08-07 | $265.41M 10-K · filed 2013-08-07 |
| 2012-02-26 | $66.89M 10-Q · filed 2013-04-04 | $135.45M derived: sum of 2 quarters · filed 2013-04-04 | $197.50M 10-Q · filed 2013-04-04 | $255.06M derived: sum of 4 quarters · filed 2013-08-07 |
| 2011-11-27 | $68.56M 10-Q · filed 2013-01-04 | $130.61M 10-Q · filed 2013-01-04 | $188.16M derived: sum of 3 quarters · filed 2013-08-07 | $249.20M derived: sum of 4 quarters · filed 2013-08-07 |
| 2011-08-28 | $62.05M 10-Q/A · filed 2013-01-02 | $119.61M derived: sum of 2 quarters · filed 2013-08-07 | $180.64M derived: sum of 3 quarters · filed 2013-08-07 | $238.95M derived: sum of 4 quarters · filed 2013-08-07 |
| 2011-05-29 | $57.55M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $118.58M derived: sum of 2 quarters · filed 2013-08-07 | $176.90M derived: sum of 3 quarters · filed 2013-08-07 | $230.03M 10-K · filed 2013-08-07 |
| 2011-02-27 | $61.03M 10-Q · filed 2012-03-28 | $119.34M derived: sum of 2 quarters · filed 2012-03-28 | $172.48M 10-Q · filed 2012-03-28 | |
| 2010-11-28 | $58.31M 10-Q · filed 2012-01-05 | $111.45M 10-Q · filed 2012-01-05 | ||
| 2010-08-29 | $53.14M 10-Q · filed 2011-10-05 | |||
| 2010-05-30 | $204.46M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |